Stock P09 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Add to a list

Consensus Pacific Biosciences of California, Inc. Deutsche Boerse AG

Stocks

P09

US69404D1081

Advanced Medical Equipment & Technology

Market Closed -
Deutsche Boerse AG
14:47:31 2026-10-01 EDT 		5-day change 1st Jan Change
2.234 EUR +7.77% Intraday chart for Pacific Biosciences of California, Inc. +80.74% +46.95%
09-16 Pacific Biosciences of California, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 04:50 PM
08-05 Pacific Biosciences of California, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: Pacific Biosciences of California, Inc.

Data source: Pacific Biosciences of California, Inc.(PACB)

Evolution of the Target Price: Pacific Biosciences of California, Inc.

Data source: Pacific Biosciences of California, Inc.(PACB)

Changes in Analyst Recommendations: Pacific Biosciences of California, Inc.

Data source: Pacific Biosciences of California, Inc.(PACB)
e943a58b1a96875f151659.tdaGMCGwOb6MW_A4aP_VwpkbQeq0C9lItQ8TAt61Zew.hO70RmXEcfzBGLlpDrPljsErDYX9U-wBxmx0YYHiNZ7j5_MFVoRs0chomw~0604eddfd845ac4807677a6ef890db15

Analysts' recommendations: Pacific Biosciences of California, Inc.

25-08-07 PacBio reports smaller-than-expected loss in Q2 RE
25-02-14 UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating MT
24-11-11 UBS Downgrades Pacific Biosciences of California to Neutral From Buy, Cuts Price Target to $2 From $12 MT
24-06-03 Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target MT
24-05-15 Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating MT
24-05-13 Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating MT
24-04-22 JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
24-04-18 Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT
24-04-18 Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7 MT
24-04-17 TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating MT
24-04-10 Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating MT
24-02-16 UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating MT
24-01-02 UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating MT
23-12-14 Guggenheim Initiates Pacific Biosciences of California With Neutral Rating MT
23-11-17 UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13 MT
23-11-06 Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating MT
23-10-31 Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14 MT
23-10-24 Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating MT
23-09-29 Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating MT
23-09-28 Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target MT
23-08-04 UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating MT
23-08-03 Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating MT
23-06-30 Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target MT
23-06-05 Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating MT
23-05-10 Barclays Initiates Pacific Biosciences of California at Equalweight With $14 Price Target MT
More recommendations


Other Advanced Medical Equipment & Technology

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock Pacific Biosciences of California, Inc.
 - - - -
THERMO FISHER SCIENTIFIC, INC. Stock Thermo Fisher Scientific, Inc.
-3.29%
DANAHER CORPORATION Stock Danaher Corporation
+4.92%
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+17.14%
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+39.75%
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+16.96%
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+1.68%
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+19.89%
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.15%
WATERS CORPORATION Stock Waters Corporation
+1.67%
Average +11.43%
Weighted average by Cap. +8.33%
See all sector performances


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.510USD
Average target price
2.157USD
Spread / Average Target
-14.06%
High Price Target
3.000USD
Spread / Highest target
+19.52%
Low Price Target
1.250USD
Spread / Lowest Target
-50.20%

Analyst Consensus Detail

Consensus revision (last 18 months)

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

B
More Ratings
  1. Stock Market
  2. Stocks
  3. PACB Stock
  4. P09 Stock
  5. Consensus Pacific Biosciences of California, Inc.

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong